**Table S2.** *EGFR* mutation status between groups of patient’s characteristics

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | ***EGFR* status in tumor tissue****(n=125)** |  | ***EGFR* status in plasma****(n=125)** |
| (-) | (+) | *P*-value |  | (-) | (+) | *P*-value |
| Age, years (median: 59; 95%CI: 57-61) |
|  | ≥59 | 28 | 29 | 0.818 |  | 33 | 24 | 0.660 |
|  | <59 | 32 | 36 |  |  | 42 | 26 |  |
| Gender |
|  | Female | 7 | 30 | **<0.001** |  | 13 | 24 | **<0.001** |
|  | Male | 53 | 35 |  |  | 62 | 26 |  |
| Ecog PS |
|  | 0–1 | 50 | 51 | 0.490 |  | 64 | 37 | 0.115 |
|  | ≥2 | 10 | 14 |  |  | 11 | 13 |  |
| Smoking status |
|  | No | 10 | 44 | **<0.001** |  | 17 | 37 | **<0.001** |
|  | Yes | 50 | 21 |  |  | 58 | 13 |  |
| Clinical stage |
|  | IIIB | 3 | 3 | 0.621 |  | 4 | 2 | 0.544 |
|  | IV | 57 | 62 |  |  | 71 | 48 |  |
| Lung metastasis |
|  | No | 41 | 45 | 0.914 |  | 52 | 34 | 0.875 |
|  | Yes | 19 | 20 |  |  | 23 | 16 |  |
| Lymph-node |
|  | No | 18 | 24 | 0.413 |  | 24 | 18 | 0.643 |
|  | Yes | 42 | 41 |  |  | 51 | 32 |  |
| Pleural effusion |
|  | No | 42 | 44 | 0.781 |  | 54 | 32 | 0.344 |
|  | Yes | 18 | 21 |  |  | 21 | 18 |  |
| Brain metastasis |
|  | No | 45 | 44 | 0.367 |  | 52 | 37 | 0.572 |
|  | Yes | 15 | 21 |  |  | 23 | 13 |  |
| Bone metastasis |
|  | No | 43 | 45 | 0.766 |  | 55 | 33 | 0.379 |
|  | Yes | 17 | 20 |  |  | 20 | 17 |  |
| Liver metastasis |
|  | No | 44 | 54 | 0.186 |  | 56 | 42 | 0.214 |
|  | Yes | 16 | 11 |  |  | 19 | 8 |  |
| Other metastasis |
|  | No | 33 | 43 | 0.202 |  | 47 | 29 | 0.601 |
|  | Yes | 27 | 22 |  |  | 28 | 21 |  |
| Tumor size |
|  | ≤5cm | 18 | 25 | 0.320 |  | 22 | 21 | 0.144 |
|  | >5cm | 42 | 40 |  |  | 53 | 29 |  |
| Treatment: chemo-radiotherapy and/or surgery |
|  | No | 27 | 42 | **0.028** |  | 33 | 36 | **0.002** |
|  | Yes | 33 | 23 |  |  | 42 | 14 |  |